Table 2. Clinical Significance of Radionuclides in Patients with Prostate Cancer.
| Radiopharmaceuticals | Clinical Significance |
|---|---|
| [68Ga]Ga-PSMA-11 | They can detect more than 80% of clinically unpredictable biochemical relapses, which could be benefit for early diagnosis, staging and curative effect of prostatic adenocarcinoma and guide clinicians to formulate personalized treatment plans. Among them, [68Ga]Ga-PSMA-I&T can detect high-grade prostatic adenocarcinoma (GS 8 or above, PSA > 10 ng/mL) sensitively and [68Ga]Ga-iPSMA-BN accumulates the least in the body. |
| [68Ga]Ga-PSMA-617 | |
| [68Ga]Ga-PSMA-I&T | |
| [68Ga]Ga-iPSMA-BN | |
| [68Ga]Ga-PSMA-TO-1 | It can improve the accuracy of early diagnosis, staging and curative effect of prostatic adenocarcinoma under the delayed imaging. |
| [68Ga]NeoBOMB1 | It stays in the tumor longer than other organs, so it can detect the prostatic adenocarcinoma and NEPC more accurately. |
| [68Ga]Ga-DOTA-NT-20.3 | They can make early diagnosis and curative effect of NEPC, including the PRRT treatment. |
| [68Ga]RM26 | |
| [18F]F-PSMA-1007 | They can sensitively detect small periurethral lesions of prostatic adenocarcinoma. |
| [18F]DCFPyL | |
| [18F]F-JK-PSMA-7 | |
| Al[18F]F-PSMA-BCH | In the absence of the Ge/Ga generator, they are easy to be prepared, which is beneficial to examination of more prostatic adenocarcinoma patient. |
| Al[18F]F-PSMA-11 | |
| [99mTc]Tc-MIP-1404 | Radiation dose of patients with prostatic adenocarcinoma can be reduced in the examination with single-photon radionuclides. |
| [99mTc]Tc-MIP-1405 | |
| [89Zr]Zr-PSMA-Df | It can improve the detection rate of lymph node metastasis near ureter, which is conducive to the accurate staging of the prostatic adenocarcinoma. |
| [89Zr]Zr-df-IAB2M | It can perform delayed imaging and can rapid from the body quickly. |
| [89Zr]4A06 | They can detect neuroendocrine prostate cancer to distinguish between different types of prostate cancer. |
| [18F]FDG | |
| [18F]FSPG | It can reflect tumor redox status and antioxidant capacity, and predict tumor chemotherapy resistance of prostatic adenocarcinoma. |
| [177Lu]Lu -PSMA-617 | These radionuclides are suitable for patients with prostatic adenocarcinoma who have already developed mCRPC. |
| [177Lu]Lu-EB-PSMA-617 | |
| [177Lu]Lu -PSMA-I&T | |
| [177Lu]Lu-PSMA-TO-1 | They can therapy prostatic adenocarcinoma and NEPC at all stages. |
| [177Lu]4A06 | |
| [177Lu]NeoBOMB1 | |
| [225Ac]Ac-PSMA-617 | They can therapy lesions that are insensitive to 177Lu-lableded pharmaceuticals. |
| [225Ac]Ac-PSMA-TO-1 | |
| [90Y]Y-DOTA-TOC | It can therapy patients with NEPC at all stages. |
There is almost no difference in the clinical significance of nuclides in the same cell. GS = Gleason score, PSA = prostate-specific antigen, NEPC = neuroendocrine prostate cancer, PRRT = peptide receptor radionuclide therapy, mCRPC = metastatic castration-resistant prostate cancer